P&G buys in to Aryx therapy

Procter & Gamble has inked a development deal with Aryx Therapeutics for Aryx's gastrointestinal disorder drug. Aryx gets $25 million up front for the licensing deal on ATI-7505, with total payments for a successful commercial launch adding up to $435 million. Aryx retains an option to co-develop and promote the therapy.

- here's the AP report on the licensing deal